- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03858127
Minipuberty and Its Effects on Preterm Neonates
Preliminary Study on Activation of the Hypothalamic-pituitary-gonadal Axis in Infancy (Minipuberty) and Its Effects on Catch-up Growth and Neurocognitive Outcome in Male Preterm Neonates Born at <32 Weeks of Gestational Age
It is generally known that there are some hormonal changes during puberty, but the knowledge about the activation of the same hormonal axis in the first months of life is relatively recent and it is not completely understood.
From the first weeks of life there is a progressive increase in hormone levels and this post-natal activation is called "minipuberty". Particularly in males, testosterone and androgen levels are associated with development and maturation of the reproductive system as well as changes in the brain structure and behaviours. Recently, it has also been suggested that the increasing testosterone level during the first 6 months of life, as well as during puberty, translates into an increase of linear growth.
In preterm neonates these hormones rise higher and for longer than in full-term newborns, suggesting that its activity is evolutionarily regulated.
With this study researchers would like to investigate these changes and correlate hormone levels with linear growth and neurobehavioral development of preterm infants.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The activation of the hypothalamic-pituitary-gonadal axis (HPG) develops through three main moments: foetal life, first postnatal months (usually first 6 months of life) and finally during puberty. During the foetal period, there is a peak of gonadotropin secretion starting from the second trimester of gestation, and a subsequent suppression in the last weeks until birth, due to the negative feedback of placental estrogens. In male foetuses, LH levels exceed those of FSH. The foetal testis secretes testosterone and anti-müllerian hormone (AMH) from the 8th week of gestation and this is essential for masculinization. Formation of the active metabolite of testosterone, dihydrotestosterone, is required for the development of the prostate, penis and scrotum. Initial testicular development is intra-abdominal and the descent of the testes into the scrotum occurs in two phases. The first, transabdominal, phase is completed by 15 weeks of gestation. The second, inguinoscrotal, phase is usually completed by the end of the 35th week of gestation and this phase is androgen dependent. Testosterone levels are high in male foetuses between 10 and 20 weeks of gestational age, reaching adult values, and decrease thereafter towards term. In the same way LH and FSH levels decrease towards the end of gestation and are low at term in both sexes, due to the negative feedback of placental oestrogens.
A second post-natal HPG activation, also called "minipuberty", occurs at around 1 week of age, when placental hormones are cleared from the circulation. From the first weeks of life onwards there is a progressive increase in gonadotropins levels with a greater increase of FSH in females and of LH in males. During the "minipuberty" period gonadotropins levels have a peak at 3 months of life and a progressive exhaustion at around 6 months, except for FSH levels in females that can remain high even up to 3 or 4 years. Particularly in males, testosterone and androgen levels are associated with development and maturation of the reproductive system (penis and testis) as well as the androgynous cutaneous manifestations and a different neurobehavioral structure. Postnatal testosterone levels have been associated with male-type behaviour in 14-month-old infants, suggesting a role in neurobehavioral development.6 Recently, it has also been suggested how the increasing testosterone level during the first 6 months of life, as well as during puberty, translates into an increase of linear growth, regardless of the levels of growth hormone (GH) or insulin-like growth factor (IGF1).
Preterm birth does not seem to influence post-natal HPG activation, since that gonadotropin levels seem to raise up at the same time as term infants after the birth. The difference is that in preterm neonates these values last higher and longer than full-term newborns. According to the most recent longitudinal data, the post-natal activity of this axis declines at about the same in term neonates compared to premature infants with the same corrected gestational age, suggesting that the HPG activity is evolutionarily regulated. This higher increase of gonadotropin levels in premature males has been associated with a faster penile and testicular growth after birth compared to full-term boys. At last, in neonates small for gestational age (SGA) there are some evidence that post-natal FSH and testosterone levels are higher compared to infants with an adequate weight (AGA), although it is not known whether this correlates or have any influence on the catch-up growth of this subjects.
Understanding how "minipuberty" can influence linear growth, genitalia development and neurocognitive processes in preterm neonates has a significant scientific impact and could provide more information in understanding auxological and neurobehavioral developmental patterns of this population.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Faisal Ahmed
- Phone Number: 07765422553
- Email: faisal.ahmed@glasgow.ac.uk
Study Contact Backup
- Name: Martina Rodie
- Phone Number: 07973887549
- Email: martina.rodie@nhs.net
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male preterm infants born ≤32 weeks of gestational age
- Written informed consent provided
Exclusion Criteria:
- Female sex assignment at birth
- Male preterm infants born >32 weeks of gestational age
- Male infants born at term
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Male infants born <32 weeks gestation
|
Collection of urine sample for measurement of LH and FSH
Examination of genitalia
Short video of infant recorded at home by the parents
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of urinary luteinising hormone
Time Frame: 18 months
|
Urinary LH measured every week on fresh samples using electro- chemiluminescence immunoassay (ECLIA).
Sample analysis will be performed by the Biochemistry Department of the Royal Hospital for Children in Glasgow using Abbott Architect i1600 instrument
|
18 months
|
Measurement of urinary follicle stimulating hormone
Time Frame: 18 months
|
Urinary FSH measured every week on fresh samples using electro- chemiluminescence immunoassay (ECLIA).
Sample analysis will be performed by the Biochemistry Department of the Royal Hospital for Children in Glasgow using Abbott Architect i1600 instrument
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of weight
Time Frame: 18 months
|
Each baby will have a naked weekly weight as part of their routine care, using calibrated weighing scales
|
18 months
|
Measurement of occipital frontal circumference
Time Frame: 18 months
|
Each baby will have a weekly OFC measured as part of their routine care using a measuring tape
|
18 months
|
Measurement of penile growth
Time Frame: 18 months
|
Each baby will have a weekly penile length measured using a measuring tape
|
18 months
|
Measurement of penile volume
Time Frame: 18 months
|
Each baby will have penile volume measured weekly using an orchidometer
|
18 months
|
Video recording of fidgety movements
Time Frame: 18 months
|
Each baby will have a 4-5 minute video recording taken by their parents for Prechtl's Method For The Qualitative Assessment Of General Movements
|
18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Paul Dearie, NHS GGC R&D
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GN18ME668P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infant, Newborn
-
Abbott NutritionInstitute of Child HealthCompleted
-
ARCIM Institute Academic Research in Complementary...University Hospital TuebingenCompleted
-
University of RochesterThe Commonwealth Fund; Academic Pediatric AssociationCompleted
-
Federal State Budget Institution Research Center...Recruiting
-
Ataturk UniversityMSc Elif Simay KOÇCompleted
-
Comenius UniversityActive, not recruitingInfant, NewbornSlovakia
-
Centre Hospitalier Universitaire, AmiensCompleted
-
University of AlbertaCompleted
-
Abbott NutritionCompleted
Clinical Trials on Collection of urine sample
-
Institut PasteurCentre Médical de l'Institut PasteurRecruiting
-
GlaxoSmithKlineCompleted
-
Changhai HospitalRenJi Hospital; Tongji Hospital; First Affiliated Hospital Xi'an Jiaotong University and other collaboratorsNot yet recruitingUrothelial Carcinoma | HematuriaChina
-
SPD Development Company LimitedCompleted
-
Unity Health TorontoCompleted
-
Masonic Cancer Center, University of MinnesotaCompletedAcute Leukemia | Chemotherapy-Induced Gut Barrier DamageUnited States
-
Medical University of ViennaCompletedFemale Stress Urinary IncontinenceAustria
-
Kevin BruceNot yet recruiting
-
IRCCS San RaffaeleUniversità Vita-Salute San RaffaeleRecruitingCarcinoma, Renal Cell | Von Hippel-Lindau DiseaseItaly
-
Benjamin GesundheitShaare Zedek Medical CenterRecruiting